CDK4 and melanoma: Furthermore, mutation or overexpression of CDK4, combined with amplification of cyclin D1, has been implicated in resistance to BRAF inhibition in V600E-mutated melanoma cells, and amplification of cyclin D1 is detected in ~17% of BRAF V600E-mutated human metastatic melanomas (12).